Loading…
Ascentage Pharma Group Internat is projected to rise to $23.65 by 2027, a +31% move from its current price of $18.07. AAPG is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $17.58 | $18.07 | $18.56 | -0.01% |
| Aug 2 | $17.39 | $18.07 | $18.77 | -0.02% |
| Aug 3 | $17.23 | $18.06 | $18.93 | -0.04% |
| Aug 4 | $17.11 | $18.06 | $19.07 | -0.05% |
| Aug 5 | $17.00 | $18.06 | $19.19 | -0.06% |
| Aug 6 | $16.90 | $18.06 | $19.30 | -0.07% |
| Aug 7 | $16.80 | $18.06 | $19.40 | -0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $16.80 | $18.06 | $19.40 | -0.08% |
| Week 2 | $16.30 | $18.04 | $19.97 | -0.16% |
| Week 3 | $15.92 | $18.03 | $20.41 | -0.25% |
| Week 4 | $15.60 | $18.01 | $20.79 | -0.33% |
| Week 5 | $15.33 | $18.00 | $21.13 | -0.41% |
| Week 6 | $15.08 | $17.98 | $21.44 | -0.49% |
| Week 7 | $14.86 | $17.97 | $21.72 | -0.57% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Ascentage Pharma Group International is a clinical-stage biotechnology company that develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.
Its primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small-molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-5918, an orally available and selective embryonic ectoderm development inhibitor.
It is involved in medical research and development; clinical development; clinical trials operations; venture capital investment; rental of buildings; and provision of science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.
Ascentage Pharma Group International (AAPG) is a clinical-stage biotechnology company focused on therapies for cancers, HBV and age-related diseases in Mainland China. The stock trades at $18.37 per share and has a market capitalization of $1.71B, with a rank of 2042.
The current price outlook is informed by a multi-year forecast. In 2026, the average price is $18.37 with a neutral sentiment and a 0 ROI. By 2030, the average rises to $31.20 with a bullish sentiment and a 69.8 ROI.
The 2040 forecast shows an average of $54.58 with a 197.1 ROI, and by 2050 the average reaches $115.21 with a 527.2 ROI, all within a bullish outlook.
These projections imply meaningful upside across the horizon, alongside inherent uncertainty and variability typical of long-horizon forecasts.
A major floor 18.2% below — a decisive break under it would weaken the trend.
The nearest floor, 7.2% below — buyers have tended to step in here.
The nearest ceiling, 12.9% above — a clean break opens room to run.
A major ceiling 51.7% above — clearing it would confirm fresh momentum.
Key AAPG support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AAPG market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $18.37 | Sell | $18.40 | Sell |
| MA 10 | $18.66 | Sell | $18.63 | Sell |
| MA 20 | $19.02 | Sell | $18.69 | Sell |
| MA 50 | $18.51 | Sell | $19.20 | Sell |
| MA 100 | $21.07 | Sell | $20.94 | Sell |
| MA 200 | $24.97 | Sell | $23.61 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.68 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -119.45 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.12 | Sell |
| ROC (12) | -6.08 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | 0.08 | Buy |
| Ultimate (7,14,28) | 36.07 | Neutral |
| Momentum (10) | -2.33 | Sell |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 18.13 | Sell |
| ADX (14) | 13.39 | Neutral |
| ATR (14) | 0.47 | Info |
The 30-day technical picture is neutral at present, with RSI14 at 50. The stock trades around a near-term midpoint, suggesting ambivalence in the immediate direction.
SMA50 is listed at $18.83 and SMA200 at $25.77, indicating prices hovering near the shorter-term average while the longer-term average sits higher. Support is identified at $16.77 and resistance at $20.40, framing a shallow near-term trading range.
The 30-day price range runs from $15.17 to $22.24, and the asset exhibits elevated volatility, with an annualized volatility figure of 60. These factors point to a tight but potentially sensitive near-term environment around current levels.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $16.77 | $18.07 | $24.14 | 0% | Neutral | |
| $18.87 | $23.65 | $31.33 | +31% | Bullish | |
| $22.30 | $28.75 | $39.53 | +59% | Bullish | |
| $22.37 | $29.50 | $41.77 | +63% | Bullish | |
| $24.57 | $33.08 | $47.99 | +83% | Bullish | |
| $25.64 | $35.16 | $52.10 | +95% | Bullish | |
| $24.00 | $33.49 | $50.58 | +85% | Bullish | |
| $28.21 | $40.00 | $61.46 | +121% | Bullish | |
| $33.42 | $48.12 | $75.12 | +166% | Bullish | |
| $35.65 | $52.09 | $82.52 | +188% | Bullish | |
| $43.09 | $67.30 | $113.41 | +272% | Bullish | |
| $80.18 | $140.39 | $258.76 | +677% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $16.77 | $18.07 | $21.06 | +0.00% |
| August 2026 | $14.98 | $17.58 | $21.11 | -2.70% |
| September 2026 | $15.11 | $17.88 | $21.75 | +1.69% |
| October 2026 | $15.83 | $18.86 | $23.19 | +5.50% |
| November 2026 | $16.01 | $19.18 | $23.78 | +1.67% |
| December 2026 | $16.05 | $19.31 | $24.14 | +0.72% |
Click any year to see its month-by-month AAPG forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, AAPG could reach as high as $24.14, with a base case around $18.07 and support toward $16.77 — roughly 0% from $18.07. Price action looks broadly range-bound.
Expect AAPG to range from $18.87 to $31.33 through 2027. The $23.65 average target implies a +31% move from current prices. That is up +31% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The AAPG price prediction for 2028 points to an average of $28.75 (low $22.30, high $39.53) — a potential gain of +59% on today's $18.07. Momentum favours further upside here.
In 2029, AAPG is projected to trade between $22.37 and $41.77, averaging $29.50 — a potential gain of +63% from today's $18.07. That is up +3% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Ascentage Pharma Group Internat's 2030 outlook centres on $33.08, within a $24.57 to $47.99 range. That is up +12% on the projected 2029 average. That marks a +83% change versus current levels. Momentum favours further upside here.
By 2031, AAPG could reach as high as $52.10, with a base case around $35.16 and support toward $25.64 — roughly +95% from $18.07. Buyers look set to stay in control over this stretch.
Expect AAPG to range from $24.00 to $50.58 through 2032. The $33.49 average target implies a +85% move from current prices. That is -5% versus the projected 2031 average. Momentum favours further upside here.
The AAPG price prediction for 2033 points to an average of $40.00 (low $28.21, high $61.46) — a potential gain of +121% on today's $18.07. Buyers look set to stay in control over this stretch.
In 2034, AAPG is projected to trade between $33.42 and $75.12, averaging $48.12 — a potential gain of +166% from today's $18.07. That is up +20% on the projected 2033 average. Momentum favours further upside here.
Ascentage Pharma Group Internat's 2035 outlook centres on $52.09, within a $35.65 to $82.52 range. That is up +8% on the projected 2034 average. That marks a +188% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, AAPG could reach as high as $113.41, with a base case around $67.30 and support toward $43.09 — roughly +272% from $18.07. Momentum favours further upside here.
Expect AAPG to range from $80.18 to $258.76 through 2050. The $140.39 average target implies a +677% move from current prices. That is up +109% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AAPG today (≈ 55.340343 AAPG) could be worth
$7,769.16
+$6,769.16 (+677%) by 2050 · US Dollar
Based on the average projected AAPG price of $140.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AAPGwould be worth at today's price.
$1,000 invested in AAPG on Jul 30, 2025 (≈ 26.666667 AAPG) would be worth
$481.87
-$518.13 (-51.8%) today · 0.48× · US Dollar
Based on a AAPG entry price of $37.5 vs. today's $18.07.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.33 | $935.06 | -6.5% |
| 1 month ago | $17.56 | $1,029.04 | +2.9% |
| 3 months ago | $23.34 | $774.21 | -22.6% |
| 6 months ago | $24.18 | $747.31 | -25.3% |
| 1 year ago | $37.5 | $481.87 | -51.8% |
| All time (1.5y) ago | $17.38 | $1,039.7 | +4.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AAPG forecast.
Our base-case forecast reaches $36.00 around 2033.
Implied market cap at $36.00: $3.36B
Looking ahead, the multi-year forecast shows a clear bullish trajectory. In 2030 the average price is $31.20 with a 69.8 ROI and a bullish sentiment, suggesting upside from the 2026 level. In 2040 the average price is $54.58 with a 197.1 ROI, continuing the bullish stance.
By 2050 the average forecast reaches $115.21 with a 527.2 ROI, still categorized as bullish. The forecasted path includes notable upside across the horizon, with the 2035 point showing an average of $45.40 and a max of $73.30, reinforcing the long-run growth expectation. The data also indicate substantial high-end potential, with a 2050 max of $217.89 and a 527.2 ROI.
Despite the optimistic long-run outlook, these are estimates and not guarantees, and the forecast includes inherent uncertainty and market volatility, as indicated by the 60 (annualized volatility) in the data.
Tap a question to reveal the answer.
2030: min $22.89, avg $31.20, max $45.92; ROI 69.8; sentiment BULLISH.
Forecasts show a rising avg price from $18.37 in 2026 to $115.21 in 2050 with ROI climbing to 527.2 by 2050; sentiment turns BULLISH after 2026. These are estimates, not guarantees.
2035: min $30.47, avg $45.40, max $73.30; ROI 147.1; sentiment BULLISH. The max forecast exceeds $50.
2026: min $16.77, avg $18.37, max $24.61; ROI 0; sentiment NEUTRAL.
2050: max $217.89, avg $115.21; ROI 527.2; sentiment BULLISH.
Ascentage Pharma Group Internat Community Discussion
0Share your Ascentage Pharma Group Internat price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.